Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Akorn to Report Fourth Quarter and Full Year 2016 Results

LAKE FOREST, Ill., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Wednesday, March 1, 2017 outlining the fourth quarter and full year 2016 results.

In addition, the Company will host a conference call at 10:00 am ET on the same day to discuss its fourth quarter and full year 2016 financial results. The dial-in number to access the call is (844) 249-9382 in the U.S. and +1 (270) 823-1530 for international callers. The conference ID is 62420433. To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

A webcast replay of the conference call will be available shortly following the conclusion of the call and will be available for 90 days following the call. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

About Akorn:

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.

Investors/Media: Stephanie Carrington ICR, Inc. (646) 277-1282 Stephanie.carrington@icrinc.com

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today